Avidity Biosciences Reports Q2 2025 Financial Results with Increased Collaboration Revenue

Avidity Biosciences, Inc. reported its financial results for the second quarter of 2025, revealing a collaboration revenue of $3.8 million, an increase from $2.0 million in the same period last year. For the first half of 2025, total revenue was $5.4 million, slightly down from $5.6 million in the first half of 2024. The company incurred a net loss of $157.3 million for the quarter, compared to a loss of $70.8 million in the prior year, and a total net loss of $273.1 million for the first six months of 2025, up from $139.6 million in the same period of 2024. The increase in losses is attributed to higher research and development expenses, which rose to $138.1 million for the quarter, up from $63.9 million a year earlier.

The company's total operating expenses for the second quarter reached $175.0 million, significantly higher than the $84.7 million reported in the same quarter of 2024. This increase was driven by a rise in both research and development costs, which included substantial investments in clinical trials and preclinical studies, and general and administrative expenses, which also saw a notable increase due to higher personnel costs and professional fees. Avidity's accumulated deficit as of June 30, 2025, stood at $1.2 billion, reflecting the ongoing investment in its product development pipeline.

In terms of operational developments, Avidity has made significant strides in its clinical programs, particularly with its Antibody Oligonucleotide Conjugates (AOCs) targeting rare diseases. The company is advancing three programs in potentially registrational trials, including delpacibart zotadirsen for Duchenne muscular dystrophy, delpacibart etedesiran for myotonic dystrophy type 1, and delpacibart braxlosiran for facioscapulohumeral muscular dystrophy. The company has also established a wholly-owned subsidiary in Ireland to support its global operations.

Avidity's cash, cash equivalents, and marketable securities totaled approximately $1.2 billion as of June 30, 2025, providing a financial cushion to support its operations for at least the next 12 months. The company plans to finance future needs through equity offerings, debt financings, and potential collaborations. In a recent development, Avidity sold over 5.6 million shares of common stock, generating net proceeds of $185.5 million, which will further bolster its financial position. Looking ahead, Avidity remains focused on advancing its clinical programs and preparing for potential product launches, with expectations of significant updates in the coming quarters.